Active Ingredient | Indication (Brand)a | Inhaler | Delivered Dose | Pharmacological Profile | Clinical Summary |
---|---|---|---|---|---|
Budesonide + formoterol (fumarate dihydrate) | Maintenance treatment of asthma (age ≥ 6 y) (USA/EU) and COPD (EU) Symbicort | pMDI (metered dose) DPI (metered dose) | 160 μg or 80 μg (bud) + 4.5 μg (for)/puff 2 puffs BID 100 or 200 μg (bud) + 6 μg (for) or 400 μg (bud) + 12 μg (for) BID (≥6–11 y lower dose only) | LABA and ICS | Prevention of symptoms and exacerbations of asthma in patients not controlled on ICS alone and COPD in patients not controlled on LABA or LAMA alone |
Beclo-methasone (diproprionate) + formoterol (fumarate dihydrate) | Maintenance + reliever treatment of asthma (age ≥ 18 y) and maintenance treatment of COPD (EU) Fostair Nexthaler | Multidose DPI (also as pMDI) | 81.9 µg (bec-pro) + 5 μg (for-fu-hydr)/actuation 1–2 act. BID, up to 4 ×/day on demand (asthma) 2 actuations BID (COPD) | LABA and ICS extrafine aerosol | Prevention of symptoms and exacerbations of asthma by symptom-guided treatment in patients not controlled on ICS alone and COPD in patients not controlled on LABA or LAMA alone |
Fluticasone (propionate) + salmeterol (xinafoate) | Maintenance treatment of asthma (age ≥ 12 y) and COPD Advair/Seretide | pMDI DPI | 45, 115, or 230 μg (flu-pro) + 21μg (sal)/puff 2 puffs BID 93, 233, or 465 μg (flu- pro) +45 μg (sal) BID, more strength available | LABA and ICS | Prevention of symptoms and exacerbations of asthma in patients not controlled on ICS alone and COPD in patients not controlled on LABA or LAMA alone |
Fluticasone (furoate) + vilanterol (trifenatate) | Maintenance treatment of asthma (age ≥ 12 y) and COPD Relvar/Breo Ellipta | DPI | 92 or 184 µg (flu-fu) + 22 μg (vil) QD | LABA and ICS | Chronic use to prevent symptoms and exacerbations of asthma in patients not controlled on ICS alone and COPD in patients not controlled on LABA or LAMA alone |
Mometasone (fuorate) + indacaterol (acetate) | Chronic treatment of asthma (age ≥ 12 y) Atectura Breezhaler | DPI | 62.5, 127.5, or 260 μg (mom-fu) + 125 μg (ind) QD | LABA and ICS | Chronic use to prevent symptoms and exacerbations of asthma in patients not controlled on ICS alone |
Mometasone (fuorate) + formoterol (fumarate dihydrate) | Maintenance treatment of asthma (age ≥ 5 y) Dulera | pMDI | 50, 100, or 200 μg (mom-fu) + 5 μg (for- fu-hydr)/puff 2 puffs BID (5–11 y lowest dose only) | LABA and ICS | Chronic use to prevent symptoms and exacerbations of asthma in patients not controlled on ICS alone |
aThe brand names are not meant to be an exhaustive list; they are provided for illustrative purposes, as different products containing the same drugs may have different quantitative compositions, formulations, devices, and overall characteristics.